Clinical Trials
5 trialsNCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT05966194 2024-11-15
KEVLARx
EpicentRx, Inc.
Phase 2 Recruiting
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT02096354 2024-10-15
ROCKET
EpicentRx, Inc.
Phase 2 Completed
NCT02452970 2024-04-24
EPIC
EpicentRx, Inc.
Phase 2 Terminated